COLL Collegium Pharmaceutical Inc.

+0.36  (+3%)
Previous Close 13.52
Open 13.56
Price To Book 5.07
Market Cap 463369970
Shares 33,371,982
Volume 125,776
Short Ratio
Av. Daily Volume 456,130

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced November 7, 2017.
Xtampza ER (oxycodone)
Severe pain
Approved April 26 2016
Xtampza ER (oxycodone)
Severe pain

Latest News

  1. Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer
  2. Collegium to Present at Upcoming Investor Conferences
  3. Read This Before Buying Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares
  4. Collegium Pharmaceutical (COLL) Upgraded to Buy: What Does It Mean for the Stock?
  5. Assertio Therapeutics, Inc (ASRT) Q4 2018 Earnings Conference Call Transcript
  6. Edited Transcript of COLL earnings conference call or presentation 27-Feb-19 9:30pm GMT
  7. Collegium Pharmaceutical Inc (COLL) Q4 2018 Earnings Conference Call Transcript
  8. Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results
  9. Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  10. ASRT or COLL: Which Is the Better Value Stock Right Now?
  11. Collegium to Host Conference Call to Discuss Fourth Quarter 2018 Financial Results and Provide Corporate Update
  12. Breakeven On The Horizon For Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
  13. ASRT vs. COLL: Which Stock Should Value Investors Buy Now?
  14. Report: Developing Opportunities within Enterprise Products Partners, Antero Midstream Partners LP, Integrated Device Technology, Collegium Pharmaceutical, GAIN Capital, and United Technologies — Future Expectations, Projections Moving into 2019
  15. Collegium Provides Full-Year 2019 Financial Guidance
  16. Do Hedge Funds Love Collegium Pharmaceutical Inc (COLL)?
  17. Edited Transcript of COLL earnings conference call or presentation 8-Nov-18 9:30pm GMT
  18. How Financially Strong Is Collegium Pharmaceutical, Inc. (NASDAQ:COLL)?
  19. Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Are Hedge Funds Right About This Stock?